Angiotensin Receptor Antagonists

• 

  Subject Areas on Research

  • A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. 
  • A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. 
  • A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. 
  • A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. 
  • ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients. 
  • ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. 
  • AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. 
  • Abnormal water metabolism in mice lacking the type 1A receptor for ANG II. 
  • Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. 
  • Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry. 
  • Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine. 
  • Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. 
  • Angioedema induced by the angiotensin II blocker losartan. 
  • Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. 
  • Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations. 
  • Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. 
  • Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. 
  • Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. 
  • Angiotensin II stimulates proliferation of adventitial fibroblasts cultured from rat aortic explants. 
  • Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. 
  • Angiotensin Receptor Blockers Were Not Associated With Decreased Arthrofibrosis After Total Knee Arthroplasty. 
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. 
  • Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. 
  • Angiotensin mediates stimulation of ventilation after vasopressin V1 receptor blockade. 
  • Angiotensin protects cortical neurons from hypoxic-induced apoptosis via the angiotensin type 2 receptor. 
  • Angiotensin-II-receptors: new targets for antihypertensive therapy. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. 
  • Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries. 
  • Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. 
  • Association Between HEDIS Performance and Primary Care Physician Age, Group Affiliation, Training, and Participation in ACA Exchanges. 
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study. 
  • Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. 
  • Association between performance measures and clinical outcomes for patients hospitalized with heart failure. 
  • Association between systolic ejection time and outcomes in heart failure by ejection fraction. 
  • Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. 
  • Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. 
  • Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. 
  • Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. 
  • Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. 
  • Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial. 
  • Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. 
  • Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Autocrine stimulation of mas oncogene leads to altered growth control. 
  • Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection Fraction. 
  • CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. 
  • Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. 
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. 
  • Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. 
  • Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease. 
  • Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. 
  • Characterization of a rat type 2 angiotensin II receptor stably expressed in 293 cells. 
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative Losartan Effects on Emphysema Progression Clinical Trial. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Combining Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blocker for Clinical Decision-making Lacks Vision. 
  • Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. 
  • Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. 
  • Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. 
  • Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. 
  • Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). 
  • Comparison of pressor responses to angiotensin I, II, and III in pulmonary vascular bed of cats. 
  • Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. 
  • Contextualizing Risk Among Patients With Heart Failure. 
  • Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. 
  • Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. 
  • Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. 
  • Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. 
  • Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. 
  • Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. 
  • Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs. 
  • Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. 
  • Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. 
  • Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. 
  • Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. 
  • Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. 
  • Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. 
  • During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. 
  • Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. 
  • Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. 
  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial. 
  • Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. 
  • Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells. 
  • Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. 
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. 
  • Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice. 
  • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 
  • Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. 
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. 
  • Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. 
  • Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. 
  • Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. 
  • Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort. 
  • Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. 
  • Essential role of AT1A receptor in the development of 2K1C hypertension. 
  • Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. 
  • Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study. 
  • Expression of renin-angiotensin system and extracellular matrix genes in cardiovascular cells and its regulation through AT1 receptor. 
  • Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. 
  • Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study. 
  • Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. 
  • From confusion to clarity: RAS blockade in patients hospitalized with COVID-19. 
  • Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team. 
  • Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. 
  • Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Heart failure medications prescribed at discharge for patients with left ventricular assist devices. 
  • Heart failure survival score in patients with Chagas disease: correlation with functional variables. 
  • Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. 
  • Hemodynamic effects of vasorelaxant compounds in mice lacking one, two or all three angiotensin II receptors. 
  • Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. 
  • Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. 
  • Hypertension. 
  • Hypertensive heart failure: patient characteristics, treatment, and outcomes. 
  • ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure. 
  • INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. 
  • Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. 
  • Impact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry®-Get With The Guidelines™ analysis. 
  • Impact of heart failure drug therapy on rates of gastrointestinal bleeding in LVAD recipients: An INTERMACS analysis. 
  • Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries. 
  • Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). 
  • Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. 
  • In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. 
  • Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. 
  • Inflammation influences vascular remodeling through AT2 receptor expression and signaling. 
  • Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat. 
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. 
  • Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity? 
  • Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. 
  • Losartan in post-transplant erythrocytosis. 
  • Losartan potassium (Cozaar). 
  • Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 
  • Mechanisms and Models in Heart Failure: A Translational Approach. 
  • Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure. 
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. 
  • Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. 
  • Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. 
  • Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. 
  • Medication-Attributable Adverse Events in Heart Failure Trials. 
  • Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans. 
  • Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF. 
  • Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. 
  • Molecular and cellular mechanism of angiotensin II-mediated apoptosis. 
  • Molecular biology of angiotensin receptors: target for drug research? 
  • Natriuretic peptides and primary prevention: the new world? 
  • Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. 
  • Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. 
  • PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. 
  • PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. 
  • Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. 
  • Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. 
  • Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. 
  • Post-Myocardial Infarction Heart Failure. 
  • Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. 
  • Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. 
  • Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. 
  • Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. 
  • Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. 
  • Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. 
  • Primary prevention implantable cardioverter-defibrillators and survival in older women. 
  • Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. 
  • Prognostic Value of Coronary CTA in Stable Chest Pain: CAD-RADS, CAC, and Cardiovascular Events in PROMISE. 
  • Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. 
  • Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. 
  • Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. 
  • Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. 
  • Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial. 
  • Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. 
  • Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 
  • Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. 
  • Renal segmental microvascular responses to ANG II in AT1A receptor null mice. 
  • Renal vascular reactivity in mice: AngII-induced vasoconstriction in AT1A receptor null mice. 
  • Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 
  • Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go? 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". 
  • Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". 
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. 
  • Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. 
  • Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. 
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. 
  • Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. 
  • Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). 
  • Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. 
  • Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. 
  • Shining More Light on RAS Inhibition during the COVID-19 Pandemic. 
  • Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. 
  • Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. 
  • Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. 
  • Synthetic nanobodies as angiotensin receptor blockers. 
  • Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. 
  • Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients. 
  • The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. 
  • The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The renin-angiotensin-aldosterone system: a specific target for hypertension management. 
  • The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. 
  • The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases. 
  • Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial. 
  • Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand. 
  • Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. 
  • Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy. 
  • Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). 
  • Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. 
  • Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. 
  • Use of combination antihypertensive therapy initiation in older Americans without prevalent cardiovascular disease. 
  • Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. 
  • Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. 
  • Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. 
  • Worsening Heart Failure Events in HFpEF: Underlying Biology Not Treatment Location. 
  • Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. 
  • [Anti-hypertensive treatment in metabolic syndrome--focus on ARB or ACE inhibitor]. 
  • [The clinical utility of angiotensin receptor blockers in out-of-office hypertension (masked hypertension, workplace hypertension, and home hypertension)]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine